ABSTRACT
INTRODUCTION
HbA1c is a measure of mean blood glucose over a period of approximately 8-10 weeks and it remains unaffected by shortterm fluctuations in blood glucose levels (1) . HbA1c is formed in two steps by the non-enzymatic glycation of HbA. The initial step is the formation of an unstable aldimine (Schiff base, labile A1c or pre-A1c), a reversible reaction. During the red blood cell circulation, some of the Schiff base is converted by Amadori rearrangement to form a stable ketoamine, HbA1c (2) . The level of HbA1c is proportional to both the average glucose concentration and the life span of the red blood cell (RBC) in circulation. Therapy for diabetes requires that the long term maintenance of blood glucose level be as close as possible to the normal level, minimizing the risk of long term vascular consequences (3, 4) . HbA1c also predicts risk of progression of diabetic complications.
Numerous studies have shown that some HbA1c methods yield inaccurate results with samples heterozygous for even HbC or S (5, 6, 7, 8, 9) . The importance of identifying the presence of a hemoglobin variant in methods used to measure HbA1c has already been emphasized (10) . On the other hand there have been studies like done by Roberts et al that concluded that Bio-Rad Variant II appears suitable for gHb determinations in diabetic patients who have either HbC or S trait (11) .
We carry out estimation of HbA1c daily on large numbers of patients, using the Variant II HbA1c program. Variant II system is a dedicated, fully automated instrument with a bar-code reader, primary tube sampling and cap piercing facility. The HbA1c program is mainly for measurements of HbA1c, but can also be used for quantitation of HbA2, HbF and presumptive detection of hemoglobin variants.
The HbA1c testing procedure suffers from the following documented limitations, as mentioned in the latest package insert: system cannot analyze homozygous samples of Hb variants (SS or CC); separation of HbA1c has been optimized to eliminate interferences from heterozygous samples of HbS & HbC, labile A1c and carbamylated hemoglobin (12) ; but other abnormal hemoglobin variants have not been fully evaluated and; levels greater than 15% of HbF may affect the resolution of HbA1c.
Since lot of studies have been done to check interference by HbAS and HbAC on HbA1c estimation, we thought to check the precision of HbA1c in cases of Hb Q India, which was first described in three Sindhi families in western India (13) . Hb Q India is characterized by mutation at codon 64 (AspoHis) in alpha globin gene of hemoglobin (14) .
MATERIALS AND METHODS
This study was carried out over a three-month period to check the precision for HbA1c, by testing eleven samples which showed an abnormal/unknown peak on Variant II. The blood samples collected in K2 EDTA (ethylenediaminetetracetic acid) vacutainers from BD, were stored at 2-8°C till analysed (maximum two days).
The glycated hemoglobin (HbA1c) was measured by Variant II Hemoglobin A1c program which utilizes the principle of ion (cation) exchange HPLC from Bio-Rad laboratories, Hercules, CA. Each sample included in the study was rechecked at least once. On the Variant II sampling station, samples are automatically mixed & diluted and injected on to the analytical cartridge. The Variant II chromatographic station dual pumps deliver a programmed buffer gradient of increasing ionic strength to the cartridge, where the hemoglobins are separated based upon their ionic interaction with the cartridge material. The separated hemoglobins then pass through the flow cell of the filter photometer, where changes in the absorbance at 415nm are measured; background variations are corrected by an additional filter at 690 nm. Two level calibration is used for adjustment of the calculated HbA1c values. A sample report and a chromatogram are generated by Clinical Data Management (CDM) software for each sample. The area of A1c peak is calculated using an exponentially modified Gaussian (EMG) algorithm that excludes the labile A1c and carbamylated peak areas from the A1c peak area.
Identification of Hb Q India was done by Beta Thal Short
Program on Variant Express, also from Bio-Rad laboratories (15) . The hemoglobin variant was further confirmed by alkaline TITAN III-H cellulose acetate electrophoresis at pH 8.2-8.6, from Helena Bio Sciences U.K (16) .
RESULTS
The HbA1c values in the study samples are mentioned in Table  1 and percentage of abnormal peaks obtained are mentioned in Table 2 respectively.
On Variant Express, all eleven samples showed a hemoglobin variant peak with retention time of 4.75 to 4.78 minutes with split A2, indicating the presence of an alpha chain variant. Classically, heterozygous hemoglobin Q India ranges from 15-17% and elutes at 4.7 minutes. Three cases out of these were also carriers for Thalassemia trait. In these three cases the value of the unknown peak was less than what is classically seen in simple heterozygous cases of Hb Q India. The hemoglobin variant was further confirmed by alkaline TITAN III-H cellulose acetate electrophoresis in which Hb Q India migrates like HbS/D/G.
DISCUSSION
The hemoglobin variants may affect the HbA1c values using HPLC by inappropriate calculation of the area of HbA, the hemoglobin variant or HbA1c due to inadequate resolution of these hemoglobin components from each other (17) . It is well known that genetic variants of hemoglobin (e.g. HbSS, HbCC) and chemically modified derivatives of hemoglobin (e.g. (18, 19) .
According to the Hemoglobin A1c program pack insert hemoglobin heterozygous variants S and C, have no clinically significant effect on the A1c values because the retention time of hemoglobins S and C are longer than HbA and the peak areas of hemoglobin S and C are not included in the calculation of total hemoglobin (10, 11) . But, other abnormal hemoglobin variants have not been fully evaluated on the Variant II TM hemoglobin A1c program.
The retention time (RT) of the unknown hemoglobin variant (Refer Table 2 ) on Variant II was 2.00 (minutes) in all samples (including rechecks). Flagging of the unknown hemoglobin variant also showed a variation, eliminating the option of flag itself being used as a warning for lack of precision in HbA1c values.
Identification of the Hb Variant:
On analyzing the data, it was observed that 7 out of 11 cases studied showed variable results of HbA1c with a mean CV of 9.93% (intra-day) which is very high and unacceptable (Refer Table 1 ). Four cases had a CV of 0.63% which is acceptable. The overall mean CV was 6.6%, which is also very high and unacceptable. The analytical measurement range (AMR) for HbA1c as provided by Bio-Rad, is 1.3-18.9 % and the intra assay coefficient of variation is < 1.46%. In this study, all the specimens had values within the AMR, but the CV is much higher than expected; though none of the samples suffered from the documented limitations. The intra assay CV observed in the precision study (all normal samples) carried out in the laboratory was 0.75%. In contrast to this, we found in this study that, 63.6% cases of Hb Q India had within run CV much greater than 1.46%, which is not acceptable, with a mean CV of 9.93%. 
